203 related articles for article (PubMed ID: 36611819)
1. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Xu K; Ding J; Zhou L; Li D; Luo J; Wang W; Shang M; Lin B; Zhou L; Zheng S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611819
[TBL] [Abstract][Full Text] [Related]
2. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.
Fang W; Song L; Li Z; Meng P; Zuo S; Liu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 47(10):1303-1314. PubMed ID: 36411681
[TBL] [Abstract][Full Text] [Related]
3. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
Zeng Y; Jiang H; Zhang X; Xu J; Wu X; Xu Q; Cai W; Ying H; Zhou R; Ding Y; Ying K; Song X; Chen Z; Zeng L; Zhao L; Yu F
Free Radic Biol Med; 2023 Nov; 208():571-586. PubMed ID: 37696420
[TBL] [Abstract][Full Text] [Related]
5. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
[TBL] [Abstract][Full Text] [Related]
6. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
[TBL] [Abstract][Full Text] [Related]
7. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
8. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
9. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
10. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
11. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
12. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
14. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract][Full Text] [Related]
15. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis.
Chen J; Ding C; Chen Y; Hu W; Lu Y; Wu W; Zhang Y; Yang B; Wu H; Peng C; Xie H; Zhou L; Wu J; Zheng S
Oncogenesis; 2020 Apr; 9(4):42. PubMed ID: 32350243
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rk1 regulates glutamine metabolism in hepatocellular carcinoma through inhibition of the ERK/c-Myc pathway.
Lu H; Yin H; Qu L; Ma X; Fu R; Fan D
Food Funct; 2022 Apr; 13(7):3793-3811. PubMed ID: 35316310
[TBL] [Abstract][Full Text] [Related]
17. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
[TBL] [Abstract][Full Text] [Related]
18. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
[TBL] [Abstract][Full Text] [Related]
20. Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.
Zuo SR; Zuo XC; He Y; Fang WJ; Wang CJ; Zou H; Chen P; Huang LF; Huang LH; Xiang H; Liu SK
J Cancer; 2018; 9(2):321-330. PubMed ID: 29344279
[No Abstract] [Full Text] [Related]
[Next] [New Search]
